Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 946 clinical trials
Featured trial
COMMANDS - Myelodysplastic Syndromes (MDS) - ACE536-MDS-002 - Australia  

The study will be conducted in compliance with the International Council for Harmonisation (ICH) of Technical Requirements for Registration of Pharmaceuticals for Human Use/Good Clinical Practice (GCP) and applicable regulatory requirements. This is an interventional active-controlled, open-label, randomized Phase 3 study to compare the efficacy and safety of luspatercept (ACE-536) …

vasectomy
erythropoietin
cancer
epoetin alfa
  • 16800 views
  • 22 Aug, 2022
  • 7 locations
A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL

This study is evaluating the efficacy of acalabrutinib in combination with bendamustine and rituximab (BR) compared with placebo plus BR in subjects with previously untreated mantle cell lymphoma.

acalabrutinib
rituximab
cyclin d1
bendamustine
  • 1317 views
  • 11 Jul, 2022
  • 30 locations
Safety and Pharmacokinetic Study of IMM0306 in Patients With Refractory or Relapsed CD20-positive B-cell Non-Hodgkin's Lymphoma (B-NHL)

The purpose of this study is to assess the safety and efficacy of IMM0306-02 in patients with refractory or relapsed CD20-positive B-cell Non-Hodgkin's Lymphoma (B-NHL).

  • 1 views
  • 26 Apr, 2022
  • 1 location
  • 0 views
  • 23 Apr, 2022
  • 1 location
Safety, Tolerability, and Efficacy of AT101 in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma

Determine MTD based on the safety and tolerability of AT101 and the RP2D for patients with recurrent or non-reactive B-cell NHL.

blood transfusion
  • 0 views
  • 04 Jun, 2022
  • 1 location
A Study of C-CAR039 in Subjects With Relapsed and/or Refractory B Cell Non-Hodgkin's Lymphoma

This is a single-center, open-label study to evaluate the safety and efficacy of C-CAR039 in relapsed and/or refractory B cell Non-Hodgkin's Lymphoma patients.

measurable disease
apheresis
neutrophil count
mantle cell lymphoma
rituximab
  • 0 views
  • 15 Dec, 2021
  • 1 location
Clinical Study of HLA Haploidentical CAR-NK Cells Targeting CD19 in the Treatment of Refractory/Relapsed B-cell NHL

To study the safety and effectiveness of HLA haploidentical CAR-NK cells targeting CD19 in patients with B-cell non-Hodgkin's lymphoma

monoclonal antibodies
diffuse large b-cell lymphoma
measurable disease
large b-cell lymphoma
mantle cell lymphoma
  • 18 views
  • 24 May, 2021
  • 1 location
Clinical Study of the Efficacy of CD19-CAR-DNT Cells in the Treatment of Relapsed/Refractory B-cell NHL

To evaluate the safety and tolerability of CD19-CAR-DNT cells infusion in subjects with relapsed/refractory B-cell non-Hodgkin's Lymphoma

platelet count
monoclonal antibodies
diffuse large b-cell lymphoma
measurable disease
fludarabine
  • 0 views
  • 24 Jul, 2022
  • 1 location
Human CD19 Targeted T Cells Injection(CD19 CAR-T) Therapy for Relapsed and Refractory B-cell Non-Hodgkin's Lymphoma

A Phase Ⅱ Clinical Study Evaluating the Efficacy and Safety of Human CD19 Targeted T Cells Injection (CD19 CAR-T) Therapy for R/R B-NHL. Patients will be given a conditioning chemotherapy

diffuse large b-cell lymphoma
fludarabine
large b-cell lymphoma
cyclophosphamide
oxygen saturation
  • 0 views
  • 25 Jul, 2022
  • 1 location
Using a Modified ALCL99 Regimen for Chinese Children With Newly Diagnosed High-risk Anapestic Large Cell Lymphoma

A prospective study on the efficacy of modified ALCL99 regimens in the treatment of the current Chinese pediatric and adolescent high-risk ALCL and compared with our historical data.

  • 0 views
  • 23 Sep, 2022
  • 1 location